Scarica l'app Stockscreener
12.60
1.86%
0.23
Pre-mercato:
12.63
0.03
+0.24%
Precedente Chiudi:
$12.37
Aprire:
$12.4
Volume 24 ore:
3.19M
Relative Volume:
0.59
Capitalizzazione di mercato:
$1.76B
Reddito:
$67.67M
Utile/perdita netta:
$-412.69M
Rapporto P/E:
-3.2927
EPS:
-3.8266
Flusso di cassa netto:
$-395.87M
1 W Prestazione:
-7.83%
1M Prestazione:
-23.96%
6M Prestazione:
+53.47%
1 anno Prestazione:
+33.19%
Intervallo 1D:
$12.35
$12.89
Intervallo di 1 settimana:
$11.79
$13.88
Portata 52W:
$6.83
$28.25
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Nome
Intellia Therapeutics Inc
Settore
Industria
Telefono
857-285-6200
Indirizzo
40 ERIE STREET, CAMBRIDGE, MA
Compare NTLA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTLA
Intellia Therapeutics Inc
|
12.60 | 1.73B | 67.67M | -412.69M | -395.87M | -3.8266 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-02 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2025-11-12 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-11 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-11-07 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-10-28 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-10-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-10-06 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-04-21 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-03-05 | Iniziato | H.C. Wainwright | Buy |
| 2025-02-28 | Downgrade | Goldman | Neutral → Sell |
| 2025-02-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-01-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-23 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-03-14 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-02-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-01-24 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-21 | Iniziato | JP Morgan | Overweight |
| 2022-09-01 | Iniziato | Citigroup | Sell |
| 2022-06-17 | Iniziato | BMO Capital Markets | Market Perform |
| 2022-06-16 | Iniziato | BofA Securities | Buy |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-02-18 | Iniziato | William Blair | Outperform |
| 2022-02-07 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2022-01-31 | Iniziato | Cowen | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
| 2021-10-05 | Iniziato | Guggenheim | Buy |
| 2021-09-24 | Iniziato | Stifel | Buy |
| 2021-06-28 | Reiterato | H.C. Wainwright | Buy |
| 2021-06-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-07 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-27 | Iniziato | Truist | Buy |
| 2020-10-14 | Iniziato | Wells Fargo | Overweight |
| 2020-09-18 | Iniziato | Goldman | Buy |
| 2020-02-28 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-14 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-11-01 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-07-09 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-10 | Iniziato | ROTH Capital | Neutral |
| 2019-05-03 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-11-02 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-10-29 | Iniziato | Credit Suisse | Neutral |
| 2018-09-21 | Iniziato | Raymond James | Mkt Perform |
| 2018-05-15 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2018-03-08 | Iniziato | JMP Securities | Mkt Outperform |
| 2017-11-01 | Reiterato | Jefferies | Buy |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2017-03-28 | Iniziato | Chardan Capital Markets | Buy |
| 2016-08-05 | Aggiornamento | Jefferies | Hold → Buy |
Mostra tutto
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Avoiding Lag: Real-Time Signals in (NTLA) Movement - Stock Traders Daily
Intellia Therapeutics’ stock rocked by patient death in gene therapy trial - MSN
Chardan Capital Maintains Intellia Therapeutics (NTLA) Buy Recommendation - MSN
Why is Intellia Therapeutics (NTLA) a Battleground Stock with 38% Short Interest - Kavout
Intellia Drops Counterclaims In Gene-Editing Patent Case - Law360
Intellia Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Intellia Dismisses Four Counterclaims in BlueAllele Patent Suit - Bloomberg Law News
Intellia Therapeutics’ SWOT analysis: gene-editing stock faces regulatory test By Investing.com - Investing.com Nigeria
Intellia Therapeutics’ SWOT analysis: gene-editing stock faces regulatory test - Investing.com
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry? - Yahoo Finance
Does Intellia Therapeutics (NTLA) Cash Runway Truly Offset Dilution Concerns From Its Recent Equity Raise? - Sahm
Buy the Rumor, Sell the News: Intellia (NTLA) Falls After Landmark Phase 3 Win - CoinCentral
Intellia Therapeutics FDA rolling application for gene therapy puts hype to test - MSN
Intellia Therapeutics says its CRISPR-based treatment succeeds in pivotal trial - MSN
NTLA Q1 earnings beat estimates, revenues miss mark, pipeline in focus - MSN
A Look At Intellia Therapeutics (NTLA) Valuation After Recent Gene Editing Trial And BLA Progress - Sahm
Intellia Therapeutics (NTLA) slides as investors digest recent earnings and dilution overhang - Quiver Quantitative
Discipline and Rules-Based Execution in NTLA Response - Stock Traders Daily
Earnings Update: Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Intellia Therapeutics, Inc. (NASDAQ:NTLA) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline - Sahm
Wells Fargo Remains a Hold on Intellia Therapeutics (NTLA) - The Globe and Mail
NTLA Maintained by Bernstein -- Price Target Raised to $17.00 - GuruFocus
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $15 to $25 - Moomoo
NTLA Maintains by HC Wainwright & Co. -- Price Target Lowered to $25 - GuruFocus
Wedbush Remains a Hold on Intellia Therapeutics (NTLA) - The Globe and Mail
H.C. Wainwright cuts Intellia Therapeutics stock price target to $25 on dilution - Investing.com Australia
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Perspective Therapeutics (CATX) - The Globe and Mail
H.C. Wainwright cuts Intellia Therapeutics stock price target to $25 on dilution By Investing.com - Investing.com South Africa
RBC Capital Keeps Their Hold Rating on Intellia Therapeutics (NTLA) - The Globe and Mail
High Growth Tech Stocks In The US For May 2026 - simplywall.st
NTLA stock rockets after hours before critical data for genetic disorder therapy - MSN
Intellia Therapeutics Price Target Cut to $49.00/Share From $58.00 by Canaccord Genuity - Moomoo
Transcript : Intellia Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03 - marketscreener.com
Cathie Wood’s ARK sells Twist Bioscience stock, buys Intellia shares - Investing.com
Cathie Wood’s ARK sells Twist Bioscience stock, buys Intellia shares By Investing.com - Investing.com India
Intellia Therapeutics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
BofA Securities Maintains Intellia Therapeutics(NTLA.US) With Hold Rating, Cuts Target Price to $19 - Moomoo
NTLA SEC FilingsIntellia Therape 10-K, 10-Q, 8-K Forms - Stock Titan
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus - TradingView
NTLA Reiterated by Wedbush -- Price Target Maintained at $12 - GuruFocus
Intellia short interest rises most among biotech stocks in latest periodBaird - Investing.com
Intellia Therapeutics Stock Short Interest Rises to 39.28% - Quiver Quantitative
NTLA jumps premarket on positive late-stage trial data for gene-editing therapy — retail says buy now before it’s too late - MSN
How Investors May Respond To Intellia Therapeutics (NTLA) Raising Capital And Advancing Its CRISPR HAE Therapy - Sahm
symbol__ Stock Quote Price and Forecast - CNN
Intellia Therapeutics Inc earnings beat by $0.10, revenue topped estimates - Investing.com South Africa
NTLA SWOT Analysis: Key Insights from the 10-Q Filing - GuruFocus
$Intellia Therapeutics (NTLA.US)$ Need to drop to 14 bf it take off.. - Moomoo
Intellia Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Intellia (NTLA) Reports Strong Q1 Revenue and Achievements in Ge - GuruFocus
Intellia Therapeutics Inc Azioni (NTLA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):